KALA BIO Halts Eye Drug Development After Trial Failure

KALA BIO’s lead drug, KPI-012, failed its Phase 2b trial for Persistent Corneal Epithelial Defect (PCED), prompting the company to stop development and pursue cash-saving strategic options.